Literature DB >> 391575

Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins.

C Mietens, H Keinhorst, H Hilpert, H Gerber, H Amster, J J Pahud.   

Abstract

A milk immunoglobulin concentrate (MIC) containing antibodies to enteropathogenic E. coli strains was prepared by hyperimmunisation of pregnant cows and using the milk obtained during the first 6 to 8 days of lactation. The sterile concentrate contained 70 to 80% protein and 35 to 40% immunoglobulin. The antibacterial activity was measured by bacterial passive agglutination, bacteriostatic activity in vitro, phagocytic clearance in vivo, and a protection test in mice. Though differences in titers were observed, adequate immunologic activity was demonstrated by these tests. Clinical studies were performed with 60 patients (aged 10 days to 18 months) suffering from diarrhoea with isolation of enteropathogenic E. coli. They were treated for 10 days with MIC and stool cultures were done prior to, during, and 2, 3 and 4 days after termination of treatment. Among 51 patients infected with E. coli strains incorporated in the vaccine, stool cultures became negative in 43 (84.3%) after treatment with MIC and 8 remained positive. Nine patients infected with strains O 78:K80(B-) and O 114:K--(B-)--which were not included in the vaccine used for immunisation--served as controls. Only one patient in this group became negative. If all patients receiving antibiotics for non intestinal infections during the treatment period are omitted the results remained unaltered: MIC was effective in 32 out of 38 patients (84.2%). These differences were highly significant. These results provide evidence that treatment with specific MIC is effective in eliminating enteropathogenic E. coli from the intestine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 391575     DOI: 10.1007/bf00496847

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

1.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

Review 2.  Host resistance factors in human milk.

Authors:  A S Goldman; C W Smith
Journal:  J Pediatr       Date:  1973-06       Impact factor: 4.406

3.  Antibodies in human milk against E. coli of the serogroups most commonly found in neonatal infections.

Authors:  J J Gindrat; L Gothefors; L A Hanson; J Winberg
Journal:  Acta Paediatr Scand       Date:  1972-09

4.  Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal.

Authors:  R C Williams; R J Gibbons
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

6.  [Adherence of pathogenic Escherichia coli to epithelial cells isolated from the intestinal mucosa of the rabbit, inhibiting effect of hyperimmune bovine colostrum and of various carbohydrates (author's transl)].

Authors:  G Demierre; D River; H Hilpert; H Gerber; R Zinkernagel
Journal:  Pathol Microbiol (Basel)       Date:  1975

7.  Enterotoxigenic Escherichia coli causing infantile enteritis in Britain.

Authors:  B Rowe; S M Scotland; R J Gross
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

8.  Pathogenesis of Escherichia coli diarrhea.

Authors:  H L DuPont; S B Formal; R B Hornick; M J Snyder; J P Libonati; D G Sheahan; E H LaBrec; J P Kalas
Journal:  N Engl J Med       Date:  1971-07-01       Impact factor: 91.245

9.  Resistance of the breast-fed infant to gastroenteritis.

Authors:  C L Bullen; A T Willis
Journal:  Br Med J       Date:  1971-08-07

10.  Proteolysis of bovine immunoglobulins.

Authors:  O de Rham; H Isliker
Journal:  Int Arch Allergy Appl Immunol       Date:  1977
View more
  23 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 4.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Resistance of bovine colostral anti-cholera toxin antibody to in vitro and in vivo proteolysis.

Authors:  R E McClead; S A Gregory
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

6.  Reactivity of human serum antibody with lipopolysaccharide O 78 antigen from enterotoxigenic Escherichia coli.

Authors:  H Brüssow; J Sidoti
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

7.  A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea.

Authors:  A Plettenberg; A Stoehr; H J Stellbrink; H Albrecht; W Meigel
Journal:  Clin Investig       Date:  1993-01

8.  Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum.

Authors:  J A Rump; R Arndt; A Arnold; C Bendick; H Dichtelmüller; M Franke; E B Helm; H Jäger; B Kampmann; P Kolb
Journal:  Clin Investig       Date:  1992-07

9.  Bovine lactogenic immunity against cholera toxin-related enterotoxins and Vibrio cholerae outer membranes.

Authors:  M Boesman-Finkelstein; N E Walton; R A Finkelstein
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

10.  Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro.

Authors:  D G Mack; R McLeod
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.